---
title: "Pharmacometric Modeling Strategies"
---

:::{.callout-caution}
# Under construction
:::

## Alternatives in PKPD modelling

* Assume a PK model
  * Estimate PK and PD parameters in a simultaneous fit (SIM)
  * Estimate PK parameters first and then fit PD
    * Condition on individual PK parameter estimates
      * Assume no error in parameters (IPP = Individual PK Parameters)
      * Account for error in parameters (IPPSE = Individual PK Parameters Standard Error) [@lacroixEvaluationIPPSEAlternative2012]
    * Fix population PK parameters
      * Include individual PK data (PPP&D = Population PK Parameters & Data)
      * Donâ€™t include individual PK data (PPP = Population PK Parameters)

Abbreviations in Zhang et al 2003 [@zhangSimultaneousVsSequential2003]  

## Important considerations

### Impact of a model [@musuambaScientificRegulatoryEvaluation2021; @skottheimrustenScientificRegulatoryEvaluation2021]

* What is the modeling used for? (e.g., bridging, dose, SmPC^[Summary of Product Characteristics] parameters?)
  * Does the conclusion align with the aim?
* What data is available?
  * Rich data
  * Sparse data
* What is the structural model?
  * Reasonable parameter estimates and RSE^[Relative standard error]'s?
  * Graphical evaluation (VPC^[Visual Predictive Check] first)
  * Covariate evaluation

* Exposure-response is generally non-informative if only one dose-level is given, even if weight-adjusted

### Reviewing models
* Does my conclusion align with the authors?
* Questions NGN (eNGiNe)
  * Need-to-know: Will affect conclusion (Major objection)
  * Good-to-know: Could affect conclusion (Other concern)
  * Nice-to-know: Won't affect conclusion (avoid asking this question)

## Terminology

### Parsimony

The idea that comparing two models, the model with fewer parameters is preferrable, given that all else is equal.

### Shrinkage

A metric which quantifies how much individual estimates regress towards the population mean under the given sampling schedule [@savicImportanceShrinkageEmpirical2009].

## References

::: {#refs}
:::
